Fulcrum Therapeutics Inc
NASDAQ:FULC
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
535.7m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
978.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.8B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
226.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
213.9B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.8B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Fulcrum Therapeutics Inc
Glance View
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).